Vnitřní lékařství, 2013 (vol. 59), issue 2

Editorial

Aortální regurgitace - editorial

R. Čerbák

Vnitr Lek 2013, 59(2):87-88

Současné trendy v léčbě a následné dispenzarizaci pacientů s diferencovaným karcinomem štítné žlázy - zkušenosti s využitím rekombinantního humánního tyreotropinu - editorial

J. Jiskra

Vnitr Lek 2013, 59(2):89-90

Představuje KDIGO Clinical practice Guideline for Glomerulonephritis přelom pro diagnostiku a léčbu glomerulonefritid? - editorial

M. Merta

Vnitr Lek 2013, 59(2):91-93

Srdeční myxomy - editorial

P. Gregor

Vnitr Lek 2013, 59(2):94-95

Měnící se přístup k léčbě AL-amyloidózy - editorial

L. Elbl

Vnitr Lek 2013, 59(2):96-98

Guidelines

Opinion of the Czech Atherosclerosis Society's committee (CSAT) on the ESC/EAS guidlines related to the diagnostics and treatment of dyslipidemias issued in 2011

V. Soška, H. Vaverková, M. Vrablík, V. Bláha, R. Cífková, T. Freiberger, P. Kraml, J. Piťha, H. Rosolová, T. Štulc, Z. Urbanová

Vnitr Lek 2013, 59(2):120-126

This position statement of the Executive Committee of the Czech Society for Atherosclerosis (CSAT) summarizes the most important aspects and novelties of the latest European guidelines for the management of dyslipidemia. In particular the position statement comments on: cardiovascular risk stratification, indications for plasma lipid and lipoprotein levels assessment as well as target lipid values, evaluation of current options for both lifestyle and pharmacological treatment of lipid metabolism disorders and, also, recommendation for laboratory monitoring of patients treated with lipid lowering agents. The statement deals with actual concepts of management...

Reviews

Aortic regurgitation

P. Gregor, H. Línková

Vnitr Lek 2013, 59(2):99-104

This paper focuses on aortic regurgitation. It covers the findings related to etiopathogenesis, clinical signs, echocardiographic and catheter examination. It analyses the treatment criteria with a focus on cardiac surgery.

Current trends in treatment and follow-up of patients with differentiated thyroid carcinoma - experience with the use of recombinant human thyrotropin

M. Macková, P. Vlček

Vnitr Lek 2013, 59(2):106-112

Differentiated thyroid carcinoma is the most common endocrine malignancy with an excellent prognosis in the case of its early detection. Radioiodine ¹³¹I and thyroid hormones continue to be the pivotal drugs in treatment and follow-up for more than 50 years. The therapeutical and diagnostic options were recently expanded by the use of recombinant human thyrotropin (rhTSH). Our experience with the diagnostic administration of rhTSH confirms the outcomes of official trials and also indicates that the effect of rational therapy with ¹³¹I after rhTSH is similar to the outcome after standard regime using long-term thyroid hormone withdrawal.

Practice guideline and trends for immunosuppressive treatment of glomerulonephritides according to KDIGO (Clinical Practice Guideline for Glomerulonephritis)

Ľ. Podracká, K. Matoušovic

Vnitr Lek 2013, 59(2):113-118

We summarize recommendations for glomerulonephritis treatment, established by internationally recognized experts in the field and sponsored by KDIGO (Kidney Disease Improving Global Outcomes). Up till now, the KDIGO review has been the most prestigious analysis of therapeutic trials on immunosuppressive treatment of glomerulonephritides. The 167 recommendations addresses the following forms of glomerulopathies: steroid-sensitive nephrotic syndrome and steroid resistant nephrotic syndrome in children; minimal change disease and idiopathic focal segmental glomerulosclerosis in children and adults; idiopathic membranous nephropathy; idiopathic membranoproliferative...

Case reports

Ischemic peripheral arterial disease and recurrent iliofemoral venous thrombosis in a 24-year-old man with antiphospholipid syndrome

D. Ručka, K. Bojanovská, S. Heller, P. Procházka, L. Skalická, P. Vařejka, M. Chochola, A. Linhart, D. Karetová

Vnitr Lek 2013, 59(2):127-131

The following is a case report of a young man with antiphospholipid syndrome, present with a recurrent iliofemoral venous thrombosis and premature peripheral arterial disease. This case report highlights the high risk of recurrent thrombosis upon discontinuation of anticoagulation therapy, particularly in the presence of persistent spontaneously increased aPTT and a high antiphospholipid antibody titer. The case report also reviews the potential of endovascular treatment of iliac vein thrombosis and points out the good 24-month patency rates of stents implanted into the pelvic vein region.

Syncope as first and only sign of left atrial myxoma

M. Samoš, M. Kňazeje, J. Dvorský, F. Kovář, P. Galajda, M. Mokáň

Vnitr Lek 2013, 59(2):132-135

Myxoma is the most frequent primary heart tumor. It is localised in the left atrium in majority of cases, but each of heart chambers may be affected. Left atrial myxoma becomes symptomatic in case it leads into mitral valve obstruction, systemic embolisation or it manifests with unspecific systemic symptoms. Echocardiography is a golden standard of myxoma diagnostics. We present a case of 61-years old woman patient in whom excercise induced syncope was the first and only sign of far gone left atrial myxoma with left ventricle inflow tract obstruction, leading to mitral pseudostenosis.

Heart transplantation and the subsequent treatment of AL amyloidosis

Z. Adam, J. Krejčí, M. Krejčí, P. Němec, L. Špinarová, V. Žampachová, Z. Čermáková, T. Pika, L. Pour, Z. Kořístek, M. Tomíška, P. Szturz, Z. Král, J. Mayer

Vnitr Lek 2013, 59(2):136-147

Severe damage to the heart caused by AL amyloid deposits is a contraindication of high-dose chemotherapy with autologous haematopoietic stem cell transplantation. Severe heart damage caused by AL amyloid results in frequent life-threatening complications, even during the course of the classical chemotherapy treatment and it often makes keeping to the treatment schedule impossible. Scheduling heart transplantation before the treatment of AL amyloidosis will significantly improve the patients' overall condition and enable them to undergo the intensive AL amyloidosis treatment with the hope that a long-term complete remission may be achieved. Case...